We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

News · February 05, 2021

High Efficacy Reported for Sputnik V COVID-19 Vaccine

Interim analysis of data from phase 3 trial shows 91.6 percent efficacy at 21 days after the first dose of the vaccine

HealthDay

 

Further Reading